Q-omics provides the consensus-scored HCG4P8 profile across patient tissues and cancer cell-line models. HCG4P8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HCG4P8 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, HCG4P8 RNA expression shows 6,711 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight MESO, and KIRC as cancer lineages where HCG4P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCG4P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCG4P8 survival associations across molecular data types. HCG4P8 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCG4P8 RNA expression–survival associations across cancer types. High HCG4P8 expression shows unfavorable associations in PAAD, UVM, THCA, GBM and STAD, but favorable associations in MESO. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for HCG4P8 RNA expression.
This table summarizes HCG4P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HCG4P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCG4P8 shows lower tumor expression in LUSC and higher tumor expression in KIRC, HNSC, THCA, KIRP and BLCA. The KIRC box plot shows higher HCG4P8 RNA expression in tumor versus normal tissue (log2 FC = +0.510, t-test p < 0.001).
This table shows molecular features associated with HCG4P8 in patient tissues and cancer cell lines. In patient samples, HCG4P8 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
